Advertisement
Advertisement
U.S. markets close in 4 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Senseonics Holdings, Inc. (SENS)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.3996+0.0796 (+3.43%)
As of 11:28AM EST. Market open.
Advertisement
Sign in to post a message.
  • G
    Gary R.N.
    To "The Moon" (상월) Thank you for what I have been saying for the past 8 months:
    #1) With FDA approval SENS will be 20 / share.
    #2) In 3-year SENS will be 300 to 500 / share.
    P.S. To our American Posters: 상월 means "The Moon" in South Korean.
    From Gary R.N.
    Bullish
  • j
    jim
    It’s about forward earnings. Stability after approval. Growth each quarter with revenue and profit increasing will determine the potential price of SENS.
  • 상월
    Wait untill FDA approval, and sell at $15-$20, or wait 3 years, and sell at $300+.THE Balls are in YOUR court!
    $SENS :
    With 445,000,000 shares out compared to DXCM's 96,000,000 shares. We have a market cap of 1.6 billion and DXCM has a market cap of 49 billion. Dexcom says they have 50% of the CGM market sewn up. If we had a share price of 100$, our market cap would be 44 billion.
    Could happen...but we need to take the market share away from the big players.
    Our revenue is definitely going up, and the 365 day study is in the works. Sensors replaced once a year with one finger stick a week.
    Could we steal a significant amount of market share from Dexcom, Abbott and Medtronic....? We shall see. Buy and hold for the long term and you may just get rewarded.It is NOW your decision to go or Not! Please be blessed, and be prepared in advance for all boarding per on time without hesitations! Glta and Very Sincerely,
  • P
    Paul
    They will announce when you least expect it.
    Better Thursday morning..pre market.
  • 상월
    $SENS: " Special and Exclusive Good News Updated" : It was exactly 2(two) year ago that $Senseonics Announced the FDA Approval to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data ,and NOW is the time for all investors here to receive the interim report of it from $SENS as one of Good News during TODAY'S presentation in which we could get some clues that 365-day Device approval timing is likely be drastically shortened than originally planned schedule among 2022 year, AND, it is also VERY clear that 180-days Device by FDA approval is very just around corner within Q2 with no issues up to now, and we could also get some GOOD NEWS of the exact timing of this FDA approval during TODAY'S presentation.
    For your information, please kindly refer to the details as below : " Strong Buy and Hold tightly and do not give any single share to Shorters and sell it until YOU are fully satisfied : See below!!!

    –The cohort of Eversense® CGM users will also test modified sensor chemistry.–
    GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the FDA approved a subgroup (with a modified chemistry to enhance longevity) of PROMISE study participants to continue for a total of 365 days to gather feasibility data on the safety and accuracy of a 365-day sensor.
    “We are very pleased that we received a prompt approval to extend the study to gather valuable data,” said Tim Goodnow, PhD, President and CEO of Senseonics. “The scientific, clinical and technical data we will obtain will be critical to further extend sensor longevity. We’re very grateful to the FDA for the green light, for the tireless clinical investigators, and particularly, to the devoted study participants for giving us this opportunity.”
    The goal of the PROMISE Clinical Study is to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the U.S. Food and Drug Administration. One hundred and eighty-one (181) study participants at 8 sites across the United States had the Eversense CGM System inserted subcutaneously as part of the study, which is completing the 180-day duration in March. Now, a sub-set of more than 35 participants who all had a sensor with the modified chemistry will be left undisturbed for 365 days with the goal of measuring accuracy and longevity over the full 365 days.
    “Extending this study is really a critical step in developing a 365-day product. Information gathered from this cohort will allow us to characterize the improved sensor design and optimize our glucose algorithm for the extended, 365-day use period,” explained Mukul Jain, PhD, Chief Operating Officer at Senseonics. “This addition is an exciting extension phase of the PROMISE study and we look forward to evaluating the first multi-clinic investigation of a one-year implantable glucose sensor.”
    The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
  • R
    Rhyen
    goodnow should have probably said in the coming months, not weeks.
    Neutral
  • a
    arjen
    green today finally. Just have patience and this will be rewarded soon
  • A
    Alon
    Yes, it was irritating to watch SENS going down with the tension took place between Russia and Ukraine (Democratic/free world and doctrine, with checks and balances, is always the solution to prevent 'courage games' played by Autocracy/Theocracy/one man show)... But as SENS has the most advanced Censor in the world and because most of diabetics wouldn't want to stab themselves all the time, if there is other good option, SENS going to be soon, with assistance of Ascensia, 'partner' of DXCM in this diabetics Multi billions global market. so 100$ per share is a very reasonable target if all would work well, as we are not talking here of an Esoteric kind of drug, but about the global Diabetes market. regarding more than that(more than 100$), it depends if Sensonics would buy it shares and pays dividends, then if all would work well, DXCM share price are not something "unrealistic." DXCM after all was in SENS shoes over 2013. and there is always the newer technology which is more friendly to the user than needles, so SENS CGM technology, Is the next link in that evolution of diabetes equipment, as I see it.
    Bullish
  • R
    Ron
    I put in a sell order for 1 share at $3.50 so I get an email when this takes off. Don't want to sell the other 30,000 shares, but I want to watch shorts burn.
  • B
    Bob
    I predict that SENS will have FDA approval for the 180 day within 180 days from today
  • 상월
    🙋🙋‍♀️🙋‍♂️SENS Moments to come up soonest! : 👉Try NOT to forget WHY many Institutions have RECENTLY increased shares drastically?: 👉JPMorgan,Barclay,BlackRock,Vanguard,Rockefeller Capital,Bank New York Mellon, CITI Group, Geode Capital... 👉Already Know it’s Going Up!!!
    👉WHY BlackRock is bought up 365% by 26,217,828 shares on August.11th.2021, and 👉WHY Bank New York Mellon up 627% by 1,121,069 shares plus JP Morgan's increase to 160,559(191.30% up), and 👉WHY Geode Capital Management' increase to 5,946,589 shares(151.43% up), Manufacturers Life Insurance Company's increase to 232,683 shares,Barclay's Plc increase to 52,557 shares(109.97% up), Proshare Advisory LLC's increase to 107,768 shares, Rockerfeller's increase to 159,187(45.79% up), 👉WHY Vangard increased its shares to 16,280,574(42.13% up) on August.13th.2021, CITI Group increase to 76,740 shares(19.49% up) and in addition, many other big Institutions, 👉Big whales & investors are also coming into SENS while such Big Catalysts and Momentums are in your pockets! 👉Strong Buy and Hold tight, and we are NOW just starting!
    👉In earnest, the pullback time is starting this week,and BooM BooM BooM time is all ready to go ~! 👉All Board per on time!///Glta.💘
  • 상월
    FDA approval : It is very clear that SENS CEO has publicly provided,on Jan.5th.2022,all investors here at SENS with this "wide open" and "official" Leakage on FDA approval with his comments on the approval by the "coming weeks",and I believe "The coming weeks" is to be applied to "Effective NOW" 😀
  • 상월
    👉Remember $TNDM's stock rise trajectory history from $3.00 to $100.00 in a time(3,300% up).Every acknowledged Analyst and knowledgeable investors are already fully aware that $SENS Sales and Marketing strategies, most adaptive & optimized SCM(Suppliers Chain Management) and his Big Visions are all much better business potential cases than other Diabetes companies' in a clear manner. 👉THIS must NOT be a Dream,but a Reality to come up soonest! 💥💥💥
  • b
    barry
    Added 300 shares 5900 shares now....waiting for over a year ...
  • R
    Ron
    Its been 3 weeks since we were told that FDA approval would be in the coming weeks. Buy more.
  • 상월
    Why I am bullish on $SENS ? 1. ASENSIA Partner with over 10 million daily customers began selling the 90 , 180 day patch in Europe. 2. SENS cash position secured 3. 90 day FDA already approved, FDA180-day to come, and soon the 365 day patch , all game changers in the Diabetes field,. 4. No competitors on the product they have. 5. Market cap very low compared to potential.
  • M
    Mike
    Even with fda approval, sens won't go over $4 with this market. Unfortunately bad timing for sens. But if you're long for 3-5 yrs then no need to worry.
  • S
    S
    We'd have to have a 40% increase to even get back to where we were the day they announced "in the coming weeks".
  • R
    Ryan
    Well raised my average again today. I am happy with my 60000 shares. Cheers!!!
  • R
    Raied
    not sure if we want the FDA approval while the market is bleeding. I hope no announcement till this is over.
Advertisement
Advertisement